(NASDAQ: IMNN) Imunon's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.38%.
Imunon's earnings in 2026 is -$14,641,555.On average, 7 Wall Street analysts forecast IMNN's earnings for 2026 to be -$13,861,527, with the lowest IMNN earnings forecast at -$17,048,833, and the highest IMNN earnings forecast at -$9,045,059. On average, 6 Wall Street analysts forecast IMNN's earnings for 2027 to be -$8,165,135, with the lowest IMNN earnings forecast at -$8,730,320, and the highest IMNN earnings forecast at -$7,191,925.
In 2028, IMNN is forecast to generate -$8,293,720 in earnings, with the lowest earnings forecast at -$12,354,227 and the highest earnings forecast at -$5,647,647.